Marco Falasca
Professor, Metabolic Signalling, Department of Medicine & Surgery Curtin University
Seminars
Wednesday 15th April 2026
Harnessing the Gut Axis: Gut-Restricted Compounds Stimulating GI Hormone Secretion
9:30 am
- Understanding how combining therapies like GLP-1 RAs and SGLT-2 inhibitors creates a synergistic effect that more effectively addresses the complex interplay of cardiovascular disease and comorbidities to move beyond the benefits of single-agent treatments to reduce major adverse cardiovascular events (MACE)
- Recognizing that combination therapies are proving beneficial across a wide range of patients, including those with and without diabetes, and those with varying degrees of obesity and chronic kidney disease to enable a more holistic and personalized strategy for improving cardiovascular health
- Grasping the compelling clinical evidence from recent trials demonstrating that this multi-drug approach provides significant, measurable reductions in MACE, all-cause mortality, and heart failure hospitalizations, fundamentally shifting the paradigm for high-risk cardiovascular patients
